-+ 0.00%
-+ 0.00%
-+ 0.00%

Lexeo Therapeutics partners with Apertura Gene Therapy for TfR1 CapX access in Friedreich ataxia program

PUBT·09/23/2026 12:02:59
Listen to the news
Lexeo Therapeutics partners with Apertura Gene Therapy for TfR1 CapX access in Friedreich ataxia program
  • Lexeo Therapeutics entered an agreement with Apertura Gene Therapy for access to TfR1 CapX for a Friedreich ataxia gene-therapy program.
  • TfR1 CapX is an intravenously delivered AAV capsid designed to target hTfR1 and cross the blood-brain barrier.
  • Lexeo plans to evaluate a less invasive CNS delivery route following initial systemic administration of LX2006.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY54973) on September 23, 2026, and is solely responsible for the information contained therein.